P-glycoprotein contributes to cell membrane depolarization of hippocampus and neocortex in a model of repetitive seizures induced by pentylenetetrazole in rats

Current Pharmaceutical Design

Volumn 19, Issue 38, 2013, Pages 6732-6738

  Auzmendi, Jerónimo A ^a   Orozco Suárez, Sandra ^b   Bañuelos Cabrera, Ivette ^c   González Trujano, María Eva ^d   González, Eduardo Calixto ^d   Rocha, Luisa ^c   Lazarowski, Alberto ^a,e  

^a Facultad de Medicina   (Argentina)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d INSTITUTO NACIONAL DE PSIQUIATRÍA RAMÓN DE LA FUENTE MUÑIZ   (Mexico)

^e University of Buenos Aires   (Argentina)

Author keywords

Epileptogenesis; Membrane Depolarization; P glycoprotein; PTZ; Refractory Epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN; PENTETRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG RESISTANT EPILEPSY; ELECTROPHYSIOLOGICAL PROCEDURES; ELECTROPHYSIOLOGY; EPILEPTOGENESIS; EXCITATORY POSTSYNAPTIC POTENTIAL; HIPPOCAMPUS; IN VITRO STUDY; LEUKEMIA CELL; MEMBRANE DEPOLARIZATION; MEMBRANE POTENTIAL; NEOCORTEX; NONHUMAN; PENTYLENETETRAZOLE-INDUCED SEIZURE; PRIORITY JOURNAL; RAT; SEIZURE; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; HUMAN; K562 CELL LINE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; CELLS, CULTURED; HIPPOCAMPUS; HUMANS; K562 CELLS; MALE; MEMBRANE POTENTIALS; NEOCORTEX; P-GLYCOPROTEIN; PENTYLENETETRAZOLE; RATS; RATS, WISTAR; SEIZURES;

EID: 84896785983     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319380006     Document Type: Article

References (47)

1. [1] Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2002; 298 (5597): 1418-21.
2. [2] Avoli M, Bernasconi A, Mattia D, Olivier A, Hwa GG. Epilepti-form discharges in the human dysplastic neocortex: in vitro physiology and pharmacology. Ann Neurol 1999; 46(6): 816-26.
3. [3] Eger Ch. Pharmacoresistance: modern concept and basic data de-rived from human brain tissue. Epilepsia 2004; 44: Suppl. 5: 9-15.
4. [4] Lazarowski A, Sevlever G, Taratuto A, Massaro M, Rabinowicz A.Tuberous sclerosis associated with MDR1 gene expression and drug-resistant epilepsy. Pediatr Neurol 1999; 21: (4): 731-4.
5. [5] Rizzi M, Caccia S, Guiso G, et al. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharma-coresistance. J Neurosci 2002; 22: 5833-9.
6. [6] Endicott JA, Ling V. The biochemistry of Pglycoprotein mediatedmultidrug resistance. Ann Rev Biochem 1989; 58: 137-71.
7. [7] Bauer B, Hartz AM, Pekcec A, Toellner K, Miller DS, Potschka H.Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol Pharmacol 2008; 73: 1444-53.
8. [8] Robey RW, Lazarowski A, Bates SE. P-glycoprotein-a clinicaltarget in drug-refractory epilepsy? Mol Pharmacol 2008; 73: 1343-6.
9. [9] Sisodiya, SM. Mechanisms of antiepileptic drug resistance. CurrOpin Neurol 2003; 16: 197-201.
10. [10] Kwan P, Sills GJ, Butler E, Gant TW, Meldrum BS, Brodie MJ. Regional expression of multidrug resistance genes in genetically epilepsy-prone rat brain after a single audiogenic seizure. Epilepsia 2002; 43(11): 1318-23.
11. [11] Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activ ity in the brain. Expert Opin Drug Metab Toxicol 2008; 4: 1245-64.
12. [12] Kunishio K, Okada M, Matsumoto Y, Nagao S, Nishiyama Y. Technetium-99m-sestamibi single photon emission computed tomography findings correlated with P-glycoprotein expression in pituitary adenoma. J Med Invest 2006; 53: 285-91.
13. [13] Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62: 3387-94.
14. [14] Chengyun D, Guoming L, Elia M, Catania MV, Qunyuan X. Expression of multidrug resistance type 1 gene (MDR1) P-glycoprotein in intractable epilepsy with different aetiologies: a double-labelling and electron microscopy study. Neurol Sci 2006; 27: 245-51.
15. [15] Björkman ST, Miller SM, Rose SE, Burke C, Colditz PB. Seizures are associated with brain injury severity in a neonatal model of hy-poxia-ischemia. Neuroscience 2010; 166: 157-67.
16. [16] Lazarowski AJ, García-Rivello HJ, Vera Janavel GL, et al. Car-diomyocytes of chronically ischemic pig hearts express the MDR-1 gene-encoded P-glycoprotein. J Histochem Cytochem 2005; 53: 845-50.
17. [17] Lazarowski A, Caltana L, Merelli A, Rubio M, Ramos A, Brusco A. Neuronal mdr-1 gene expression after experimental focal hy-poxia: a new obstacle for neuroprotection?. J Neurol Sci 2007; 258: 84-92.
18. [18] Wadkins RM, Roepe PD. Biophysical aspect of P-glycoprotein mediated multidrug resistance. Int Rev Cytol 1997; 171: 121-65.
19. [19] Roepe PD. What is the precise role of human MDR 1 protein in chemotherapeutic drug resistance? Curr Pharm Des 2000; 6: 241-60.
20. [20] Vanoye C, Castro A, Pourcher T, Reuss L, Altenberg G. Phos-phorylation of P-glycoprotein by PKA and PKC modulates swelling-activated Cl- currents. Am J Physiol 1999; 276: C370-C378.
21. [21] Müller M. Effects of chloride transport inhibition and chloride substitution on neuron function and on hypoxic spreading-depression-like depolarization in rat hippocampal slices. Neurosci-ence 2000; 97: 33-45.
22. [22] Le Duigou C, Bouilleret V, Miles R. Epileptiform activities in slices of hippocampus from mice after intra-hippocampal injection of kainic acid. J Physiol 2008; 586: (Pt 20): 4891-904.
23. [23] Neerati P, Ganji D, Bedada SK. Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with vera-pamil in rats. Eur J Pharm Sci 2011; 44: 27-31.
24. [24] Onod, JM, Nelson KK, Taylor JD, Honn KV. In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis diamminedichloroplatinum(II). Cancer Res 1989; 49: 2844-50.
25. [25] Arunasree KM, Roy KR, Anilkumar K, Aparna A, Reddy GV, Reddanna P. Imatinib-resistant K562 cells are more sensitive to celecoxib, a selective COX-2 inhibitor: role of COX-2 and MDR-1. Leuk Res 2008; 32: 855-64.
26. [26] Rocha L, Ackermann RF, Engel JJr. Chronic and single administration of pentylenetetrazol modifies benzodiazepine receptor-binding: an autoradiographic study. Epilepsy Res 1996; 24: 65-72.
27. [27] Calixto E, Thiels E, Klann E, Barrionuevo G. Early maintenance of hippocampal mossy fiber-long-term potentiation depends on protein and RNA synthesis and presynaptic granule cell integrity. J Neurosci 2003; 23: 4842-9.
28. [28] Wilson H, Chused T.. Lymphocyte membrane potential and Ca2+-sensitive potassium channels described by oxonol dye fluorescence measurements. J Cell Physiol 1985; 125: 72-81.
29. [29] Bortner CD, Gomez-Angelats M, Cidlowski JA. Plasma membrane depolarization without repolarization is an early molecular event in anti-Fas-induced apoptosis. J Biol Chem 2001; 276: 4304-14.
30. [30] Willmott NJ, Wong K, Strong AJ. Intercellular Ca2+ waves in rat hippocampal slice and dissociated glial-neuron cultures mediated by nitric oxide. FEBS Letters 2000; 487: 239-47.
31. [31] Lazarowski A, Ramos AJ, García-Rivello H, Brusco A, Girardi E. Neuronal and glial expression of the multidrug resistance gene product in an experimental epilepsy model. Cell Mol Neurobiol 2004; 24: 77-85.
32. [32] Liu X, Yang Z, Yang J, Yang H.Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of penty-lenetetrazole-kindled rats. Neuropharmacology 2007; 53: 657-63.
33. [33] Höcht C, Lazarowski A, Gonzalez NN, et al. Nimodipine restores the altered hippocampal phenytoin pharmaco-kinetics in a refractory epileptic model. Neurosci Lett 2007; 413 168-72.
34. [34] Höcht C, Lazarowski A, Gonzalez NN, et al. Differential hippo-campal pharmacokinetics of phenobarbital and carbamazepine in repetitive seizures induced by 3-mercaptopropionic acid. Neurosci Lett 2009; 453(1): 54-7.
35. [35] Mizutani T, Masuda M, Nakai E, et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab 2008; 9: 167-74.
36. [36] Valverde MA, Diaz M, Sepulveda FV, Gill DR, Hyde SC, Higgins CF. Volume-regulated chloride associated with the human multidrug-resistance P-glycoprotein. Nature 1992; 355: 830-3.
37. [37] Siesjö BK, von Hanwehr R, Nergelius G, Nevander G, Ingvar M. Extra- and intracellular pH in the brain during seizures and in the recovery period following the arrest of seizure activity. J Cereb Blood Flow Metab 1985; 5: 47-57.
38. [38] Durand DM, Park EH, Jensen AL. Potassium diffusive coupling in neural networks. Philos Trans R Soc Lond B Biol Sci 2010; 365: 2347-62.
39. [39] Prince DA, Connors BW. Mechanisms of interictal epileptogenesis. Adv Neurol 1986; 44: 275-99.
40. [40] Luna-Munguia H, Orozco-Suarez S, Rocha L. Effects of high frequency electrical stimulation and R-verapamil on seizure susceptibility and glutamate and GABA release in a model of phenytoin-resistant seizures. Neuropharmacology 2011; 61: 807-14.
41. [41] Czuczwar SJ, Gasior M, Janusz W, Kleinrok Z. Influence of flu-narizine, nicardipine and nimodipine on the anticonvulsant activity of different antiepileptic drugs in mice. Neuropharmacology 1992; 31: 1179-83.
42. [42] De Falco FA, Bartiromo U, Majello L, Di Geronimo G, Mundo P. Calcium antagonist nimodipine in intractable epilepsy. Epilepsia 1992; 33, 343-5.
43. [43] Kulak W, Sobaniec W. Anticonvulsant effects of calcium antagonists in the experimental seizures in the rat. Neurosci Jpn1993; 19: 107-12.
44. [44] Gasior M, Kamiñski R, Brudniak T, Kleinrok Z, Czuczwar SJ. Influence of nicardipine, nimodipine and flunarizine on the anti-convulsant efficacy of antiepileptics against pentylenetetrazole in mice. J Neural Transm 1996; 103: 819-31.
45. [45] Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr 2008; 8: 127-30.
46. [46] Rocha L, Briones M, Ackermann RF, et al. Pentylenetetrazol-induced kindling: early involvement of excitatory and inhibitory systems. Epilepsy Res 1996; 26: 105-13.
47. [47] Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007; 48 Suppl 5: 140-9.